Sarah A. Morrow

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

Raju Kapoor, Pei‐Ran Ho, Nolan Campbell et al. · The Lancet Neurology · 2018 · 337 citations · Full text

Life Sciences, Neurology, Pharmacotherapy +14

Predicting loss of employment over three years in multiple sclerosis: clinically meaningful cognitive decline

Sarah A. Morrow, Allison Drake, Robert Zivadinov et al. · The Clinical Neuropsychologist · 2010 · 253 citations

Medicine, Neurology, Cognitive Neurology +16

Cognitive reserve moderates decline in information processing speed in multiple sclerosis patients

Ralph H. B. Benedict, Sarah A. Morrow, Bianca Weinstock Guttman et al. · Journal of the International Neuropsychological Society · 2010 · 150 citations

Medicine, Neurology, Neuroscience +17

Unmet needs, burden of treatment, and patient engagement in multiple sclerosis: A combined perspective from the MS in the 21st Century Steering Group

Diego Centonze, Irina Elovaara, Gavin Giovannoni et al. · Multiple Sclerosis and Related Disorders · 2017 · 140 citations · Full text

Pharmacy, Neurology, Health Services Research +12

The Validity and Reliability of the Neurogenic Bladder Symptom Score

Blayne Welk, Sarah A. Morrow, Wendy Madarasz et al. · The Journal of Urology · 2014 · 135 citations

Medicine, Urology, Neurourology +16